Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, 7SL, cytoplasmic 216, pseudogene (RN7SL216P) is a non-coding RNA sequence found on human chromosome 3[2]. It is part of a large family of pseudogenes derived from the functional signal recognition particle RNA gene (7SL RNA), which is important in protein targeting within cells[1][3]. Most 7SL RNA pseudogenes in human DNA, including RN7SL216P, are thought to result from the reverse transcription and integration of RNA sequences back into the genome[7]. These pseudogenes are typically truncated, lack expression, and do not produce functional RNA or protein products, making them non-functional in biological processes[2][5][7]. No alternative names, disease roles, drug interactions, or biomarker uses have been described for RN7SL216P. Key points: - RN7SL216P is classified strictly as a pseudogene, not a functional receptor, protein, or drug target[2][5][7]. - No known aliases, functions, disease links, or drug interactions. - Entry is likely inappropriate as a therapeutic target due to pseudogene status; this is a common issue when pseudogenes are confused with functional molecule targets.
None—no drugs target this pseudogene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, 7SL, cytoplasmic 216, pseudogene (RN7SL216P).